Gromit Therapeutics

Gromit Therapeutics is a clinical stage bio-pharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases across human and animal healthcare. We own a proprietary platform technology targeting aging, inflammation and senescence, focused at delivering a therapeutic gene that has demonstrated strong clinical efficacy and safety in treating cardiovascular, pulmonary and orthopedic conditions. An ongoing clinical study enrolled over thirty patients to date, and collected initial evidence of safety and efficacy outcomes, with a follow-up period of over a year. The companion animals enrolled in the studies have exhausted all possible surgical or medical treatments and some were about to be euthanized before successfully treated with Gromit Therapeutics gene therapy. These findings will provide foundation for veterinary drug development and support a number of IND applications for human indications. We have recently reached an exclusive license agreement with the Icahn School of Medicine at Mount Sinai in New York, NY to a broad patent portfolio related to Sphingolipids metabolizing enzyme (SME) and its therapeutic application in senescence, inflammation and aging. This high value technology has been developed in the lab of Efrat Eliyahu, PhD, Assistant Professor of Genetics and Genomics Sciences at Icahn Mount Sinai, and is addressing acute and chronic inflammatory diseases and related conditions. The therapeutic protein is administered as gene therapy via using adeno-associated-virus mediated delivery. Icahn Mount Sinai will continue to partner with Gromit to support Gromit-funded research and clinical efforts that leverage Icahn Mount Sinai’s extraordinary expertise and facilities. Our technology is also supported by multiple peer reviewed publications, clinical and scientific collaborations and NIH grants.